Format

Send to

Choose Destination
J Surg Oncol. 2016 Sep;114(3):275-80. doi: 10.1002/jso.24331. Epub 2016 Jun 22.

Importance of cost-effectiveness and value in cancer care and healthcare policy.

Author information

1
Department of Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.

Abstract

The cost of cancer care has increased by five fold over the last three decades. As our healthcare system shifts from volume to value, greater scrutiny of interventions with clinical equipoise is required. Traditionally, QALYs and ICER have served as surrogate markers for value. However, this approach fails to incorporate all stakeholders' viewpoints. Prostate cancer, low risk DCIS, and thyroid cancer are used as a framework to discuss value and cost-effectiveness. J. Surg. Oncol. 2016;114:275-280.

KEYWORDS:

ICER; QALY; ductal carcinoma in-situ; prostate cancer; thyroid cancer; value

PMID:
27334052
PMCID:
PMC5048466
DOI:
10.1002/jso.24331
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center